In this installment of BenchTalk, we take a look at how well antibodies are validated today and what you should be concerned about when selecting different antibodies for your research. Through interviews with David Rimm, professor of pathology at Yale University, and Andrew Bradbury, a staff member at Los Alamos National Lab, the need for proper antibody validation and the potential impact on the research community when antibodies are not properly validated are discussed.
For additional information on antibody validation, take a look at the 2010 review article from David Rimm and colleagues detailing a pipeline for proper antibody validation as well as this recent news article highlighting the impact of improper validation on basic research.
Podcast Date: November 26 2013 Run Time:
Cell Culture: Why Does It Remain Difficult? | BenchTalk, Episode 10 New York, NY
Cancer Stem Cells | BenchTalk, Episode 9 New York, NY
Optogenetics: Shining a Light on Neuroscience | BenchTalk, Episode 8 New York, NY
Advances in the Determination of Protein Structures | BenchTalk, Episode 7 New York, NY
RNA Editing Controversy: Benchtalk, Episode 6 New York, NY
Genomics in the Cloud: Benchtalk, Episode 5 New York, NY